Engineered cytokines for immuno-oncology indications
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
100
NCT06779851
A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 15, 2024
Completion: Dec 31, 2028
Loading map...